Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.875
Bid: 2.75
Ask: 3.00
Change: -0.025 (-0.86%)
Spread: 0.25 (9.091%)
Open: 3.00
High: 3.00
Low: 2.74
Prev. Close: 2.90
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

2 Jun 2017 12:55

RNS Number : 0263H
Allergy Therapeutics PLC
02 June 2017
 

 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Allergy Therapeutics PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

S

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

¨

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

¨

An event changing the breakdown of voting rights

¨

Other (please specify):

¨

3. Full name of person(s) subject to thenotification obligation: iii

BlackRock, Inc.

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

1 June, 2017

6. Date on which issuer notified:

2 June, 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

Voting rights attached to shares holding for BlackRock Investment Management (UK) Limited has gone above 5%

 

Total holding for BlackRock Investment Management (UK) Limited has gone above 5%

 

Voting rights attached to shares holding for BlackRock, Inc. has gone above 5%

 

Total holding for BlackRock, Inc. has gone above 5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B02LCQ05

Below 5%

Below 5%

N/A

N/A

30,368,413

N/A

5.11%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

30,368,413

5.11%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

See Annex 1

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

BlackRock Regulatory Threshold Reporting Team

14. Contact name:

Marc-Oliver Lesch

15. Contact telephone number:

020 7743 3650

Annex 1

 

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock International Holdings, Inc.

BR Jersey International Holdings L.P.

BlackRock Group Limited

BlackRock Investment Management (UK) Limited

5.11%

5.11%

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUUVARBSANRAR
Date   Source Headline
8th Jul 20167:00 amRNSResults of mite immunotherapy Acarovac PlusT
27th Jun 20167:00 amRNSFindings from mEEC dose range finding study G204
13th Jun 20167:00 amRNSAllergy hosts Satellite Symposium at EAACI
10th Jun 20167:00 amRNSAppointment of Finance Director
9th May 20167:00 amRNSPositive Phase II Data
23rd Mar 20169:02 amRNSIssue of equity in respect of options exercise
17th Mar 20167:00 amRNSBoard Change
11th Mar 20164:36 pmRNSGrant of Options under Long Term Incentive Plan
8th Mar 20167:00 amRNSInterim Results for the six months ended 31/12/15
24th Feb 20167:30 amRNSHardman & Co Research Report: Development Progress
23rd Feb 20167:00 amRNSNotice of Interim Results
18th Feb 20167:00 amRNSPatient enrolment completed in US Phase IIb study
13th Jan 20167:00 amRNSTrading Update
7th Dec 20157:00 amRNSUS Phase II study for GrassMATAMPL initiated
2nd Dec 20153:47 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSPQBirch204 Phase II study update
27th Nov 20153:21 pmRNSHolding(s) in Company
25th Nov 20156:06 pmRNSGrant of Options under Long Term Incentive Plan
18th Nov 201512:23 pmRNSResult of AGM
17th Nov 201512:51 pmRNSResults of Placing
17th Nov 20157:01 amRNSProposed placing to raise up to £12 million
17th Nov 20157:00 amRNSTrading Update
4th Nov 20157:00 amRNSWorld Vaccine Congress Presentation
21st Oct 20152:48 pmRNSHardman & Co issues research report
16th Oct 20157:00 amRNSAnnual Report and Accounts
21st Sep 20157:00 amRNSFinal Results
1st Sep 20157:04 amRNSFirst patient recruited in PQ Birch dose study
10th Aug 20157:00 amRNSKey paper published in the World Allergy Journal
27th Jul 20157:00 amRNSDirector Share Dealings
23rd Jul 20157:00 amRNSNotice of Results and Trading Update
6th Jul 20157:00 amRNSPositive Dust Mite Study Results
2nd Jul 20157:00 amRNSCompany to Host Key Allergy Conference
25th Jun 20157:00 amRNSCompany to resume US clinical programme
5th Jun 201510:59 amRNSAcquisition of Alerpharma S.A.
9th Apr 20155:51 pmRNSHolding(s) in Company
8th Apr 20153:47 pmRNSHolding(s) in Company
1st Apr 20153:20 pmRNSHolding(s) in Company
30th Mar 201511:27 amRNSResult of General Meeting and Issue of Equity
10th Mar 20157:03 amRNSIssue of Equity
2nd Mar 20157:00 amRNSHalf Yearly Report
30th Jan 20153:58 pmRNSHolding(s) in Company
12th Jan 20157:00 amRNSTrading Update
16th Dec 20142:00 pmRNSChange of Adviser
19th Nov 20141:16 pmRNSResult of AGM
18th Nov 20147:00 amRNSAppointment of a Non-Executive Director
5th Nov 20147:00 amRNSGrant of Options
4th Nov 20147:00 amRNSAppointment of Head of Clinical Science
23rd Oct 20143:19 pmRNSAnnual Report and Accounts
8th Oct 20147:44 amRNSDirectorate Change
1st Oct 201412:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.